SCHEMBL18219989

SCHEMBL18219989

COCCNC(=O)/C(C#N)=C(\C)c1ccc2cc(N3CCN(C)CC3)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.49
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
RXFP1 Q9HBX9 2/20 0.42
PRKD1 Q15139 1/20 0.42
HTR1A P08908 2/20 0.40
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MEN1 O00255 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24075174 0.92 APP (0.42) APPNPC1RAB9AHTR1AKMT2A
SCHEMBL18219999 0.91 APP (0.48) APPNPC1RAB9ARXFP1KMT2A
SCHEMBL20306932 0.91 APP (0.43) APPNPC1RAB9AHTR1AKMT2A
SCHEMBL18220010 0.90 PRKD1 (0.46) NPC1RAB9ARXFP1PRKD1KMT2A
SCHEMBL18220000 0.90 APP (0.49) APPKMT2AMAPTHPGDTSHR
SCHEMBL18220447 0.86 APP (0.54) APPNPC1RAB9ARXFP1KMT2A
SCHEMBL29663432 0.86 APP (0.54) APPNPC1RAB9ARXFP1KMT2A
SCHEMBL17099824 0.86 APP (0.54) APPNPC1RAB9ARXFP1KMT2A
SCHEMBL17099842 0.86 APP (0.54) APPNPC1RAB9ARXFP1KMT2A
SCHEMBL17099829 0.86 APP (0.54) APPNPC1RAB9ARXFP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
EP-3119761-B1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME AMYDIS DIAGNOSTICS INC (US) 2023-06-07 EP disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 APP 1/4885NPC1 993/4885RAB9A 2146/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 APP 1/4885NPC1 993/4885RAB9A 2146/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA APP 1/4885NPC1 1111/4885RAB9A 2191/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA APP 1/4885NPC1 1111/4885RAB9A 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.